Ilika starts shipping new Stereax solid-state battery

Ilika has commenced shipping prototype Stereax M300 solid-state batteries to 21 customers, marking an initial commercial milestone and supporting its ten-year manufacturing agreement with Cirtec Medical signed in August 2023. Production has been transferred to Cirtec’s Lowell, Massachusetts facility, with a portion of early output earmarked for internal testing for active implantable medical devices; management highlights this as a step to intensify customer engagement and service implantable power-management applications.

Analysis

Market structure: Ilika (AIM:IKA / OTCQX:ILIKF) and its contract manufacturer Cirtec are the direct winners — 21 initial customers and a transfer to a Lowell, MA facility signal de-risked manufacturing and premium pricing power in the niche implantable micro‑battery market. Incumbent button/coin‑cell suppliers (smaller legacy microbattery makers) and early-stage pouch‑cell suppliers for medical microsensors face marginal displacement risk, but near‑term market share shifts will be small because addressable volumes remain limited (units in the low thousands over 12 months). Cross‑assets impact is muted: commodities (lithium/cobalt) insensitive, UK small‑cap sentiment may tick up (AIM flows), and IKA equity implied volatility should compress on execution clarity while credit markets are unaffected.

Key Decisions for Investors

• Establish a tactical long position equal to 1.5–2.5% of portfolio in Ilika (AIM:IKA or OTCQX:ILIKF) with a 12–24 month horizon; use a hard stop at -30% and plan to scale up to 4% only if Ilika reports recurring quarterly revenue >£1.5m or Cirtec confirms sustained production yields >90% within 6 months.
• If options liquidity exists, buy 6–12 month call spreads (buy 25–35% OTM, sell 60–90% OTM) sized to ~0.5% portfolio risk to cap downside while retaining upside; if no options, pair the equity long with a 0.5–1% long in Medtronic (MDT) or Boston Scientific (BSX) as M&A/strategic‑partner hedges.
• Monitor three binary catalysts over the next 90–180 days and act: (A) first reported commercial revenue quarter (buy an additional 1–2% if revenue growth >20% QoQ), (B) any FDA/CE qualification notice (add 1% and trim other speculative AIM medtech exposure by 50%), (C) any manufacturing shortfall or recall (sell entire position if Ilika explicitly pulls guidance or Cirtec halts production).